Will the current measles vaccines ever eradicate measles?

Expert Review of Vaccines

Volumn 1, Issue 3, 2002, Pages 355-362

  Stephenson, John ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Children; Deafness; Encephalitis; Live attenuated vaccine; Measles; MMR

Indexed keywords

MATERNAL ANTIBODY; MEASLES MUMPS RUBELLA VACCINE; MEASLES VACCINE;

ALLERGIC REACTION; AUTISM; CHILD; CONJUNCTIVITIS; DEVELOPED COUNTRY; DRUG EFFICACY; DRUG UPTAKE; ENCEPHALITIS; ENTERITIS; ERADICATION THERAPY; EVIDENCE BASED MEDICINE; FEBRILE CONVULSION; FEVER; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNIZATION; INDUSTRY; INFECTION PREVENTION; MEASLES; MEDICAL SOCIETY; MYELITIS; OPTIC NERVE DISEASE; PATHOGENESIS; PERCEPTION DEAFNESS; PRIORITY JOURNAL; RASH; REVIEW; RISK FACTOR; SUBACUTE SCLEROSING PANENCEPHALITIS; THROMBOCYTOPENIA; THROMBOCYTOPENIC PURPURA; TROPICAL DISEASE; VACCINATION;

AUTISTIC DISORDER; CROHN DISEASE; HUMANS; IMMUNIZATION SCHEDULE; MEASLES; MEASLES VACCINE; MEASLES VIRUS; VACCINES, ATTENUATED;

EID: 0038330623     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.1.3.355     Document Type: Review

References (55)

1. Curts FT, Steinglas R. Should measles be eradicated? Br. Med. J. 316, 765-767 (1998).
2. Clements CJ, Cutts FT. The epidemiology of measles: thirty years of vaccination. In: Measles virus. ter Meuler V, Billiter MA, (Eds), Springer-Verlag, Berlin, Germany, 13-34 (1995).
3. Major R. A history of medicine. Thomas, Springfield, 238-239 (1954).
4. Grenfell BT, Bjornstad ON, Jappy J. Travelling waves and spatial hierarchies in measles epidemics. Nature 414, 717-723 (2001).
5. Katz M. Clinical spectrum of measles,. In: Measles virus. ter Meulen V and Billiter MA, (Eds), Springer-Verlag, Berlin, Germany, 1-12 (1995).
6. Arguedas AG, Deveikis AA, Marks MI. Measles. Am. J. Inf. Control 19, 290-298 (1991).
7. Cherry JD. Measles. In: Textbook of paediatric diseases. Feigin RD, Cherry JD. (Eds), WB Saunders, Philadelphia, PA, USA, 1608-1628 (1987).
8. O'Donovan C, Barua KN. Measles pneumonia. Am. J. Trop. Med. Hyg. 22, 73-77 (1973).
9. Johnson RT, Griffin DE, Hirsch RL Measles encephalomyelitis - clinical and immunologic studies. N. Eng. J. Med. 310, 137-141 (1984).
10. Engelking O, Fedorov LM, Lilischkis R, ter Meulen V, Schneider-Schaulies S. Measles virus-induced immunosuppression in vitro is associated with deregulation of G1 cell cycle control proteins. J. Gen. Virol 80, 1599-1608 (1999).
11. Von Pirquet CE. Das verhalten der kutanen tuberkulin-reaktion wahrendder masern. Deutsche Med. Wachnschr. 34, 1297 (1908).
12. ter Meulen V, Stephenson JR, Kreth HW. Subacute sclerosing panencephalitis. In: 'Comprehensive Virology', 18. Fraenkel, Wagner (Eds) Plenum Press, New York, NY, USA, 105-160 (1983).
13. Greenfield JG. Encephalitis and encephalomyelitis in England and Wales during the last decade. Brain 73, 141.
14. Monif GR, Hood CL. Ileocolitis associated with measles (rubeola). Am. J. Dis. Child. 102, 245-247 (1970).
15. Atkinson WL, Orenstein WA. The resurgence of measles in the United States, 1989-1990. Ann. Rev. Med. 43, 451-463 (1992).
16. Enders JF, Pebles TC. Propogation in tissue cultures of cytopathogenic agents from patients with measles. Proc. Soc. Exp. Biol. Med. 86, 277-286 (1954).
17. Markowitz LE, Ornstein LA. Measles vaccines. Pediatr. Clin. North Am. 37, 603-625 (1990).
18. Duclos P, Ward BJ. Measles vaccines: a review of adverse events. Drug Safety 19, 436-453 (1998).
19. Whittle HC, Mann G, Eccles M et al. Effects of dose and strain of vaccine on success of measles vaccination of infants aged 4-5 months. Lancet 1, 963-966 (1988).
20. Rota JS, Wang ZD, Rota P, Bellini WJ. Comparison of sequences of the H F and N coding genes of measles virus vaccine strains. Virus Res. 31, 317-330 (1994).
21. Wood DL, Brunell PA. Measles control in the United States: problems of the past and challenges for the future. Clin. Microbiol. Rev. 8, 260-267 (1995).
22. Markowitz LE, Preblud SR, Fine PEM, Orenstein WA. Duration of live measles vaccine-induced immunity. Pediatr. Infect. Dis. 9, 101-110 (1990).
23. De Quadros CA, Olive JM, Hersh BS et al. Measles elimination in the Americas, evolving strategies. J. Am. Med. Assoc. 275, 224-229 (1996).
24. Cutts FT, Markowitz LE. Successes and failures in measles control. J. Inf. Dis. 170 (Suppl. 1), S32-S41 (1994).
25. Cutts FT, Henao-Restrepo AM, Olive JM. Measles elimination: progress and challenges. Vaccine 17, S47-S52 (1999).
26. Hayden GF, Sato PA, Wright PF, Henderson RF. Progtess in worldwide control of disease through immunisation. J. Pediatr. 114, 520-527 (1989).
27. Biellim R, Madema S, Taole A et al. First 5 years of measles elimination in Southern Africa: 1996-2000. Lancet 359, 1564-1568 (2002).
28. Black FL, Berman LL, Borgono JM. Geographic variation in infant loss of maternal measles antibody and in prevalence of rubella antibody. Am. J. Epidemiol. 124, 442-452 (1986).
29. Halsey NA. Increased mortality after high titre measles vaccines: too much of a good thing. Pediatr. Infect. Dis. J. 12, 462-465 (1993).
30. Cutts FT, Clements CJ, Bennett JV. Alternative routes of measles immunisation: A review. Biologicals 25, 323-338 (1997).
31. Mitchell VS, Philipose NM, Sanford JP (Eds). The Children's Vaccine Initiative, Achieving the vision. National Academy Press, Washington DC, USA (1993).
32. Children's Vaccine Initiative ad hoc committee on an investment strategy for measles control. A Bellagio consensus. J. Infect. Dis. 170, S63-S64 (1994).
33. Hutchins S, Markowitz L, Atkinson W, Swint E, Hadler S. Measles outbreaks in the United States, 1987 through 1990. Pediatr. Infect. Dis. 15, 31-38 (1996).
34. Centers for Disease Control. Measles prevention: recommendations of the Immunisation Practices Advisory Committee (ACIP). Morbid. Mortal. Wkly Rep. 38, 1-18 (1990).
35. Sheldon T. Netherlands faces measles epidemic. Br. Med. J. 320, 76 (2000).
36. Anon. Outbreaks of measles in communication with low vaccine coverage. Commun. Dis. Rep. Wkly 10, 29 (2000).
37. Anon. Laboratory confirmed cases of measles, mumps and rubella, England and Wales: January to March 2002. CDR Wkly 12, 26 (2002).
38. Fenichel GM. Neurological complications of immunisations. Ann. Neurol. 12, 119-128 (1982).
39. Chen RT, Haber P, Mullen JR. Surveillance of the safety of simultaneous administration of vaccines, the Centers for Disease Control and prevention Experience. Ann. NY Acad Sci. 754, 309-320 (1995).
40. Vessel S, Kravis LP. Immunologic mechanisms responsible for adverse reactions to routine immunisations in Children. Clin. Pediatr. 15, 688-696 (1976).
41. Freigang B, Jadvji TP, Freigang DW. Lack of adverse reactions to measles, mumps and rubella vaccine in egg-allergic children. Ann. Allergy 73, 486-488.
42. Pampiglione G, Griffith A, Bramwell EC. Transient cerebral changes after vaccination against measles. Lancet 2, 5-8 (1971).
43. da Silveira CM, Salisbury DM, de Quadros CA. Measles vaccination and Guillain-Barré syndrome. Lancet 349, 14-6 (1997)
44. Isacson P, Stone A. Allergic reactions associated with viral vaccines. Prog. Med. Virol. 13, 239-270 (1971).
45. Wakefield AJ, Pittilo RM, Sim R et al. Evidence of persistent measles virus infection in Crohn's disease. J. Med. Virol. 39, 345-353 (1993).
46. Afzal MA, Minor PM, Schild GC. Clinical safety issues of measles, mumps and rubella vaccines. Bull. World Health Organ. 78 (2), 199-204 (2000).
47. Iizuka M, Nakagomi O, Chiba M. Absence of measles virus in Crohn's disease. Lancet 345, 199 (1995)
48. Metcalf J. Is measles infection associated with Crohn's disease? The current evidence does not support a causal link. Br. Med. J. 316, 166 (1998).
49. Lione A, Scialli AR. Perinatal exposure to measles virus and the risk of inflammatory bowel disease. Reprod. Toxicol. 11, 647-652 (1997).
50. Sartor RB, Rath HC, Sellon RK. Microbial factors in chronic intestinal inflammation. Curr. Opin. Gastroenterol. 12, 327-333 (1996).
51. Fudenberg HH. Dialysable lymphocyte extract (DLyE) in infantile onset autism: a pilot study. Biotherapy 9, 143-147 (1996).
52. Wakefield AJ, Murch SH, Anthony A. Ileal-lymphoid-nodular hyperplasia, non-specific colitis and pervasive developmental disorder in children. Lancet 351, 637-641 (1998).
53. Department of Health, England and Wales. MMR vaccine is not linked to Crohn's disease or autism: conclusion of an expert scientific seminar, London, UK. Press release 98/109 March 24 (1998).
54. MRC Review of autism research, epidemiology and causes. The Medical Research Council, London, UK (2001).
55. Donald A, Muthu V. Measles vaccination. Clin. Evid. 7, (2002)